Cannabis Science Negotiates a Total 360,000 Sq. Ft. Licensed Cannabinoid Grow and Formulation Processing in Nevada, Including Facilities for Educational and Medical Clinic and Laboratory for Drug Development Programs Targeting Multiple Critical Ailments
Last update: 24/03/2016 12:08:33 pm
Cannabis Science Negotiates a Total 360,000 Sq. Ft. Licensed Cannabinoid Grow and Formulation Processing in Nevada, Including Facilities for Educational and Medical Clinic and Laboratory for Drug Development Programs Targeting Multiple Critical Ailments
COLORADO SPRINGS, CO--(Marketwired - Mar 24, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced the Company has negotiated a major new drug development and facilities deal in the State of Nevada. The premises include an approximately 360,000 sq. ft. licensed cannabinoid grow and a separate formulation processing operation in Nevada. The transaction includes access to a separate educational and research facility for its drug development programs targeting critical ailment research initiatives.
All parties involved are motivated and excited to get this landmark deal underway. It gives the Company and its investor partners access to over 360,000 sq. ft. of fully-licensed land for cannabis grow operations and full access to an educational, laboratory, and medical clinic location for formulation processing and further critical ailment research.
"The goal is to bring our cannabinoid formulations across the country and internationally 'much faster' and more efficiently, and, in addition, to improve the Company's output capacity from a manufacturing standpoint. Sometimes opportunity just falls in your lap when you persevere in 'doing the right thing.' So now we move forward with this massive deal, which covers a large amount of land. We at Cannabis Science are so excited to see our widespread rollout strategy starting to come to fruition. This Nevada opportunity was a complete surprise as we were more focused on targeting California expansions; however, of course when new and fortuitous circumstances present themselves, you must be fluid, open and respond accordingly. This is what we did. The added capacity this development deal and others like it provides should allow us to rapidly move into a much larger development and production capacity, to continue the advancement of our drug development programs while we provide our important formulations to patients in need sooner and in greater geographic areas," stated Cannabis Science President & CEO, Co-Founder Raymond C. Dabney.
This added capacity will allow the Company to further its drug development programs more quickly. The Company has targeted current success with a few critical ailments including Cancer, PTSD, HIV/AIDS, Autism, and Neurological disorders, utilizing and monitoring different cannabinoid formulations and delivery modules. The Company will have a much wider base to work from by expanding into the State of Nevada, drawing another very large targeted medical consumer base.
"We have a few more landmark growth agreements underway, such as our California initiatives that are advancing nicely. The Company has more watershed operational changes to announce upon completion. We have a few more pleasant surprises to compound our growth and solidify our position in this outstanding cannabis-based pharmaceutical industry growth curve. We understand our position and we know what needs to get done. We are excited, we are motivated, and we are on the move, in the right direction. We look forward to keeping everyone up to date with all our progress. Again we wish to thank our shareholders for their continued support along this amazing path," concluded Mr. Dabney.
